Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers
Latest Information Update: 21 Nov 2024
Price :
$35 *
At a glance
- Drugs Bintrafusp alfa (Primary) ; CV 301 (Primary) ; Nogapendekin alfa inbakicept (Primary) ; PDS 0301 (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- 21 Aug 2024 Status changed from active, no longer recruiting to completed.
- 23 Oct 2023 Planned End Date changed from 31 Jul 2024 to 31 Jan 2026.
- 23 Oct 2023 Status changed from completed to active, no longer recruiting.